Episode 22. Management of Low-Risk MDS
Blood Cancer Talks · Rajshekhar Chakraborty, Ashwin Kishtagari, and Edward Cliff
Audio is streamed directly from the publisher (media.transistor.fm) as published in their RSS feed. Play Podcasts does not host this file. Rights-holders can request removal through the copyright & takedown page.
Show Notes
In this episode, we take a deep dive into low-risk MDS management. We have the privilege of being joined by the esteemed Dr. Mikkael Sekeres. We also explore his invaluable insights gained from his time at FDA ODAC and his latest literary endeavor, "Drugs and the FDA".
Here are the key studies discussed:
1. ASH choosing wisely:
https://www.hematology.org/education/clinicians/guidelines-and-quality-care/choosing-wisely
2. International Consensus Classification (ICC):
https://pubmed.ncbi.nlm.nih.gov/35767897/
3. WHO classification 2022:
https://pubmed.ncbi.nlm.nih.gov/35732829/
4. IPSS-M:
https://evidence.nejm.org/doi/full/10.1056/EVIDoa2200008
5. Romiplostim in MDS:
https://pubmed.ncbi.nlm.nih.gov/29396092/
6. Low-dose decitabine vs. low-dose azacItidine in lower-risk MDS:
https://evidence.nejm.org/doi/full/10.1056/EVIDoa2200034
7. Luspatercept in MDS:
https://www.nejm.org/doi/full/10.1056/nejmoa1908892
8. Lenalidomide in MDS:
https://ascopubs.org/doi/10.1200/JCO.2015.66.0118
https://pubmed.ncbi.nlm.nih.gov/21753188/
9.Iron chelation therapy in MDS:
https://pubmed.ncbi.nlm.nih.gov/32203980/